ISSN: 0443-511
e-ISSN: 2448-5667
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Liraglutida y glimepirida para el control glucémico de la diabetes tipo 2. Análisis de la cohorte mexicana de LEAD-3

Pedro García-Hernández, María Del Rosario Arechavaleta-Granell, Jorge Yamamoto, Ali Falahati, Guillermo González-Gálvez


Objetivo: se comparan la eficacia de la liraglutida y de la glimepirida en sujetos con diabetes mellitus tipo 2 controlados inadecuadamente. 

Métodos: estudio prospectivo en Estados Unidos y México, con 52 semanas de seguimiento, doble ciego, controlado con activo, de grupo paralelo, multicéntrico, que incluyó a 746 sujetos. En México, 171 sujetos fueron asignados de manera aleatoria (1:1:1) a liraglutida (1.2 o 1.8 mg/día vía subcutánea) o a glimepirida (8 mg/día vía oral).

Resultados: en sujetos mexicanos, la HbA1c se redujo 0.64, 1.31 y 0.30 % con glimepirida, 1.8 mg de liraglutida y 1.2 mg de liraglutida, respectivamente. El peso corporal disminuyó 1.99 y 1.98 kg con 1.2 y 1.8 mg de liraglutida, respectivamente; mientras que hubo ganancia de 0.94 kg con glimepirida. La glucosa plasmática en ayuno se redujo 27.9 mg/dL (1.55 mmol/L) con 1.8 mg de liraglutida y se elevó 9.54 mg/dL (0.53 mmol/L) con glimepirida. Con liraglutida ocurrieron episodios hipoglucémicos menores en menos individuos No se registraron episodios hipoglucémicos importantes. 

Conclusiones: en sujetos mexicanos con diabetes tipo 2, la monoterapia con liraglutida redujo más la HbA1c, hubo más pérdida de peso y menor riesgo de hipoglucemia que con glimepirida.

Palabras clave

Incretinas; Diabetes; Glucemia

Texto completo:



UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44:1249-1258. 


Nathan DM, Buse JB, Davidson MB, Heine RJ, Hol-man RR, Sherwin R, et al. Management of hyper-glycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-1972.


Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract. 2007; 61:3-11.


Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355:2427-2443.


UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.


Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther. 2005; 27  (Suppl B):1-18.


Rolfing CL, Wiedmeyer HS, Little RR, England JD, Tennill A, Goldstein DE, et al. Defining the relationship between plasma glucose and HbA1c. Diabetes Care. 2002; 25:275-278.


Holst JJ. Enteroglucagon. Annu Rev Physiol. 1997; 59:257-271.


Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987; 2 (8571):1300-1304.


Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckle D, Schmidt WE, Gallwitz B. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004; 53:654-662. 


Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87:1409-1439.


Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharma-cokinetic properties suitable for once daily adminis-tration. J Med Chem. 2000; 43:1664-1669.


Agerso H, Jensen LB, Elbrond B, Rolan P, Zdrav-kovic M. The pharmacokinetics, pharmacodyna-mics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabe-tologia 2002;45:195-202.


Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of GLP-1 which have extended metabolic stability and improved biological activity. Diabetologia. 1998; 41:271-278. 


Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmaco-dynamics, safety and tolerability of a single dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male patients. Diabetes Care 2002;25:1398-1404. 


Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006; 368:1696-1705.


Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med. 2009; 121 (3):5-15.


World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assemble, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General Assembly, Tokyo 2004. Disponible en http//


International Conference on Harmonisation. ICH Harmonised Tripartite Guideline, Good Clinical Practice, 1996. Disponible en


Garber A, Henry R, Ratner R; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373 (9662): 473-481.


Davies M. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord. 2004; 28 (Suppl 2): S14-S22.


Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidylpeptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368 (9548):1696-1705.

Enlaces refback

  • No hay ningún enlace refback.